Open Navigation
Close Navigation
Timely, relevant updates from CGT experts on common challenges or questions from patients and advocates.
ASGCT experts discuss approved products, eligibility criteria, CAR-T lessons, provider knowledge, and how CGTs excite families compared to current sickle cell care.
The informed consent process (ICP) is a crucial step before participating in a clinical trial, and ensures the treatment and trial process is well understood by patients and their families before they agree to participate.
2023 was an exciting year for the field, but what do all these approvals mean for access, safety, and long-term outcomes in the communities they affect?
Learn from our experts highlighting the unique impact genetic testing has for disease groups like Duchenne Muscular Dystrophy (DMD), giant axonal neuropathy (GAN), and Angelman syndrome.